Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 22, 2016

Seroprotection status of hepatitis B and measles vaccines in children with type 1 diabetes mellitus

  • Zerrin Onal EMAIL logo , Atilla Ersen , Elvan Bayramoglu , Selcen Yaroglu Kazancı , Hasan Onal and Erdal Adal



Type 1 diabetes mellitus (T1DM) is speculated to have an impaired immunological response to vaccines. This paper aimed to investigate the presence of specific antibodies against hepatitis B virus (HBV) and measles in diabetic children who had been immunized according to the standard national calendar of immunization.


Two hundred and one diabetic children and 140 healthy controls were prospectively evaluated. Antibodies against hepatitis B (anti-HBs) and measles were detected in all individuals who completed the vaccination schedule. We noted onset of T1DM, duration of the disease, diabetes-related autoantibodies and mean HbA1c levels.


Some 72.6% of diabetics and 82.1% of controls had anti-HBs (+) (p=0.04). We found a reduced efficacy of measles vaccination in anti-HBs (–) diabetic children (p=0.009), even though there was no significant difference between the study and control groups. Onset of the disease was earlier in anti-HBs (–) diabetics than in controls (p=0.038). No difference with respect to other parameters was found.


Our data showed a reduced seroprotection rate for HBV vaccination in diabetic children and for measles with anti-HBs (–) diabetics. Larger studies should be encouraged to confirm the vaccine efficacy in diabetic children and to elucidate possible pathogenic mechanisms.

Corresponding author: Zerrin Onal, MD, Kanuni Sultan Suleyman Training and Research Hospital, Department of Pediatrics, Kınalıtepe sok simitaş 7.blok no:61, Merter, Istanbul, Turkey, Phone:+ 90 532 509 29 88, Fax: +90 212 414 31 77

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


1. Hiltunen M, Lönnrot M, Hyöty H. Immunisation and type 1 diabetes mellitus: is there a link? Drug Saf 1999;20:207–12.10.2165/00002018-199920030-00001Search in Google Scholar

2. Salemi S, D’Amelio R. Could autoimmunity be induced by vaccination? Int Rev Immunol 2010;29:247–69.10.3109/08830181003746304Search in Google Scholar

3. Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 2005;23:3876–86.10.1016/j.vaccine.2005.03.005Search in Google Scholar

4. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004;350:1398–404.10.1056/NEJMoa032665Search in Google Scholar

5. Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2–4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J Pediatr Endocrinol Metab 2003; 16:495–508.10.1515/JPEM.2003.16.4.495Search in Google Scholar

6. Hiltunen M, Hyöty H, Leinikki P, Akerblom HK, Tuomilehto J, et al. Low mumps antibody levels induced by mumps-measles-rubella vaccinations in type 1 diabetic children. DiabetMed 1994;11:942–6.10.1111/j.1464-5491.1994.tb00251.xSearch in Google Scholar

7. Leonardi S, Vitaliti G, Garozzo MT, Miraglia del Giudice M, Marseglia G, et al. Hepatitis B vaccination failure in children with diabetes mellitus? The debate continues. Hum Vaccin Immunother 2012;8:448–52.10.4161/hv.19107Search in Google Scholar

8. Douvin C, Simon D, Charles MA, Deforges L, Bierling P, et al. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997;20:148–51.10.2337/diacare.20.2.148Search in Google Scholar

9. Marseglia G, Alibrandi A, d’Annunzio G, Gulminetti R, Avanzini MA, et al. Long term persistence of anti-HBs protective levels in young patients with type 1 diabetes after recombinant hepatitis B vaccine. Vaccine 2000;19:680–3.10.1016/S0264-410X(00)00268-1Search in Google Scholar

10. Halota W, Muszyńska M, Pawłowska M. Hepatitis B virus serologic markers and anti-hepatitis B vaccination in patients with diabetes. Med Sci Monit 2002;8:CR516–9.Search in Google Scholar

11. Arslanoğlu I, Cetin B, Işgüven P, Karavuş M. Anti-HBs response to standard hepatitis B vaccination in children and adolescents with diabetes mellitus. J Pediatr Endocrinol Metab 2002;15: 389–95.10.1515/JPEM.2002.15.4.389Search in Google Scholar PubMed

12. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994;331:1428–36.10.1056/NEJM199411243312107Search in Google Scholar

13. Foulis AK, Stewart JA. The pancreas in recent-onset type 1 (insulin-dependent) diabetes mellitus: insulin content of islets, insulitis and associated changes in the exocrine acinar tissue. Diabetologia 1984;26:456–61.10.1007/BF00262221Search in Google Scholar

14. Jansen A, van Hagen M, Drexhage HA. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995;345:491–2.10.1016/S0140-6736(95)90586-3Search in Google Scholar

15. Takahashi K, Honeyman MC, Harrison LC. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. J Immunol 1998;161:2629–35.10.4049/jimmunol.161.5.2629Search in Google Scholar

16. Litherland SA, Xie XT, Hutson AD, Wasserfall C, Whittaker DS, et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999;104:515–23.10.1172/JCI4852Search in Google Scholar PubMed PubMed Central

17. Wilson SB, Kent SC, Patton KT, Orban T, Jackson RA, et al. Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature 1998;391:177–81.10.1038/34419Search in Google Scholar PubMed

18. Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab Res Rev 2003;19:89–100.10.1002/dmrr.341Search in Google Scholar PubMed

19. Ramondetti F, Sacco S, Comelli M, Bruno G, Falorni A, et al; RIDI Study Group. Type 1 diabetes and measles, mumps and rubella childhood infections within the Italian Insulin-dependent Diabetes Registry. Diabet Med 2012;29:761–6.10.1111/j.1464-5491.2011.03529.xSearch in Google Scholar PubMed

20. Rewers M, Atkinson M. The possible role of enteroviruses in diabetes mellitus. In: Rotbart HA, editor. Human enterovirus infections. Washington, DC: American Society for Microbiology, 1995:353–85.Search in Google Scholar

21. Cohen AD, Shoenfeld Y. Vaccine-induced autoimmunity. J Autoimmun 1996;9:699–703.10.1006/jaut.1996.0091Search in Google Scholar PubMed

22. Kubba AK, Taylor P, Graneek B, Strobel S. Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 2003;6:106–12.Search in Google Scholar

23. Wood RC, MacDonald KL, White KE, Hedberg CW, Hanson M, et al. Risk factors for lack of detectable antibody following hepatitis B vaccination of minnesota health care workers. J Am Med Assoc 1993;270:2935–9.10.1001/jama.1993.03510240047030Search in Google Scholar

24. Zanoni G, Contreas G, Valletta E, Gabrielli O, Mengoli C, et al. Normal or defective immune response to hepatitis B vaccine in patients with diabetes and celiac disease. Hum Vaccin Immunother 2014;11:708–12.10.4161/hv.34309Search in Google Scholar PubMed PubMed Central

25. Leonardi S, Spina M, Spicuzza L, Rotolo N, La Rosa M. Hepatitis B vaccination failure in celiac disease: is there a need to reassess current immunization strategies? Vaccine 2009;27:6030–3.10.1016/j.vaccine.2009.07.099Search in Google Scholar

26. Zanetti AR, Mariano A, Romanò L, D’Amelio R, Chironna M, et al; Study Group. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet 2005;366:1379–84.10.1016/S0140-6736(05)67568-XSearch in Google Scholar

27. Stachowski J, Kramer J, Füst G, Maciejewski J, Baldamus CA, et al. Relationship between the reactivity to hepatitis B virus vaccination and the frequency of MHC class I, II and III alleles in haemodialysis patients. Scand J Immunol 1995; 42:60–5.10.1111/j.1365-3083.1995.tb03626.xSearch in Google Scholar PubMed

28. Ada G. Vaccines and vaccination. N Engl J Med 2001;345: 1042–53.10.1056/NEJMra011223Search in Google Scholar PubMed

29. Pozzilli P, Arduini P, Visalli N, Sutherland J, Pezzella M, et al. Reduced protection against hepatitis B virus following vaccination in patients with type 1 (insulin-dependent) diabetes. Diabetologia 1987;30:817–9.10.1007/BF00275749Search in Google Scholar PubMed

30. Bouter KP, Diepersloot RJ, Wismans PJ, Gmelig Meyling FH, Hoekstra JB, et al. Humoral immune response to a yeast-derived hepatitis B vaccine in patients with type 1 diabetes mellitus. Diabet Med 1992;9:66–9.10.1111/j.1464-5491.1992.tb01717.xSearch in Google Scholar PubMed

31. Fiçicioğlu C, Mikla S, Midilli K, Aydin A, Cam H, et al. Reduced immune response to hepatitis B vaccine in children with insulin dependent diabetes. Acta Paediatr Jpn 1995;37:687–90.10.1111/j.1442-200X.1995.tb03404.xSearch in Google Scholar PubMed

32. Elrashidy H, Elbahrawy A, El-Didamony G, Mostafa M, George NM, et al. Antibody levels against hepatitis B virus after hepatitis B vaccination in Egyptian diabetic children and adolescents. Hum Vaccin Immunother 2013;9:2002–6.10.4161/hv.25426Search in Google Scholar PubMed PubMed Central

33. Hyöty H, Hiltunen M, Reunanen A, Leinikki P, Vesikari T, et al. Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measles-rubella vaccine in Finland. Diabetologia 1993;36:1303–8.10.1007/BF00400810Search in Google Scholar PubMed

Received: 2016-1-5
Accepted: 2016-7-18
Published Online: 2016-9-22
Published in Print: 2016-9-1

©2016 Walter de Gruyter GmbH, Berlin/Boston

Downloaded on 26.2.2024 from
Scroll to top button